Hao-Yuan Chuang, Chief Financial Officer and Director of Belite Bio, Inc (NASDAQ:BLTE), filed a Form 4 on August 14, 2026, disclosing the sale of 367 American depositary shares on August 12, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Two sale transactions: Chuang sold 144 American depositary shares at $180.00 and 223 American depositary shares at $180.57, both on August 12, 2026.
  • Rule 10b5-1 plan: The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2025.
  • Remaining ownership: Following the transactions, Chuang directly beneficially owned 93,433 American depositary shares.
  • Security details: Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.
  • Roles: Chuang is identified in the filing as both a Director and Chief Financial Officer of Belite Bio, Inc.

Belite Bio CFO Discloses ADS Sales Under Pre-Established Trading Plan

According to the Form 4 filed with the SEC on August 14, 2026, Hao-Yuan Chuang, who serves as both Chief Financial Officer and Director of Belite Bio, Inc (NASDAQ:BLTE), reported two sales of American depositary shares on August 12, 2026. The first transaction involved 144 shares sold at $180.00 per share, and the second involved 223 shares sold at $180.57 per share, for a combined total of 367 shares disposed of on that date.

The filing notes that both sales were made directly and were "effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/22/2025." The filing also indicates the checkbox confirming the transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) was checked. Following the two reported transactions, the filing discloses that Chuang directly and beneficially owned 93,433 American depositary shares.

The filing further explains that each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer. No derivative securities transactions were reported in Table II of the filing. The Form 4 was signed by Chuang on August 14, 2026, and was filed as an individual, not a joint or group filing.

What Was Disclosed

Belite Bio's CFO and Director Hao-Yuan Chuang reported the sale of 367 American depositary shares on August 12, 2026, in two separate transactions at prices of $180.00 and $180.57, under a pre-established Rule 10b5-1 plan adopted December 22, 2025, leaving a remaining direct beneficial ownership of 93,433 shares.